RA
STIM icon

Royce & Associates’s Neuronetics STIM Stock Holding History

Royce & Associates’s Portfolio STIM Stock Details STIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-253,500
Closed -$768K – 982
2022
Q1 		$768K Sell
253,500
-133,000
-34% -$450K 0.01% 835
2021
Q4 		$1.72M Buy
386,500
+50,000
+15% +$245K 0.01% 746
2021
Q3 		$2.21M Sell
336,500
-670,694
-67% -$6.43M 0.02% 728
2021
Q2 		$16.1M Sell
1,007,194
-19,400
-2% -$268K 0.11% 320
2021
Q1 		$12.7M Buy
1,026,594
+92,036
+10% +$1.41M 0.09% 383
2020
Q4 		$10.4M Buy
934,558
+754,558
+419% +$5.67M 0.09% 362
2020
Q3 		$875K Buy
+180,000
New +$683K 0.01% 792

Other funds holding STIM

CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
ACM
Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PGM
Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return
MAG
Millrace Asset Group Berwyn, Pennsylvania $98.4M AUM 63.71% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FWC
First Washington Corp Seattle, Washington $353M AUM 41.46% 1-Year Est. Return

Royce & Associates's STIM Position: Q2 2022 in Review

Royce & Associates sold out of Neuronetics (STIM) in Q2 2022, closing a stake of 253,500 shares — an estimated $768K sold.

Royce & Associates first reported a position in STIM in Q3 2020 and held it in 7 quarters. The position peaked at $16.1M in Q2 2021. 77 funds tracked by Wall St. Rank hold STIM as of Q2 2022.

  • Royce & Associates reported no remaining Neuronetics position as of Q2 2022 after selling out during the quarter.
  • Royce & Associates sold 253,500 Neuronetics shares in Q2 2022, an estimated $768K.
  • Royce & Associates first reported a position in Neuronetics in Q3 2020 and held it in 7 quarters.
  • Royce & Associates's Neuronetics position peaked at $16.1M in Q2 2021.
  • 77 funds tracked by Wall St. Rank held Neuronetics as of Q2 2022.

Based on Royce & Associates's 13F filing for Q2 2022, filed 4 Aug 2022.